CN101248998B - 一种真空采血管 - Google Patents
一种真空采血管 Download PDFInfo
- Publication number
- CN101248998B CN101248998B CN2008101031552A CN200810103155A CN101248998B CN 101248998 B CN101248998 B CN 101248998B CN 2008101031552 A CN2008101031552 A CN 2008101031552A CN 200810103155 A CN200810103155 A CN 200810103155A CN 101248998 B CN101248998 B CN 101248998B
- Authority
- CN
- China
- Prior art keywords
- hirudin
- blood
- vacuum
- tube
- blood taking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004369 blood Anatomy 0.000 claims abstract description 168
- 239000008280 blood Substances 0.000 claims abstract description 168
- 108010007267 Hirudins Proteins 0.000 claims abstract description 74
- 229940006607 hirudin Drugs 0.000 claims abstract description 72
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims abstract description 70
- 102000007625 Hirudins Human genes 0.000 claims abstract description 69
- 238000012360 testing method Methods 0.000 claims abstract description 42
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 40
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 38
- 238000004458 analytical method Methods 0.000 claims abstract description 23
- 238000001514 detection method Methods 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 5
- 238000003757 reverse transcription PCR Methods 0.000 claims abstract description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 3
- 150000001413 amino acids Chemical group 0.000 claims abstract description 3
- 239000007864 aqueous solution Substances 0.000 claims abstract description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 14
- 238000005507 spraying Methods 0.000 claims description 5
- 230000015271 coagulation Effects 0.000 claims description 3
- 238000005345 coagulation Methods 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 208000035992 Postmortem Changes Diseases 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 27
- 238000000855 fermentation Methods 0.000 description 23
- 230000004151 fermentation Effects 0.000 description 23
- 239000007921 spray Substances 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 21
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 description 18
- 229960004408 lepirudin Drugs 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 108090000190 Thrombin Proteins 0.000 description 14
- 229960004072 thrombin Drugs 0.000 description 14
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 13
- 230000002429 anti-coagulating effect Effects 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 210000000601 blood cell Anatomy 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000001471 micro-filtration Methods 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 239000012488 sample solution Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000701 coagulant Substances 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 108010025188 Alcohol oxidase Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000007979 citrate buffer Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 241000700721 Hepatitis B virus Species 0.000 description 4
- 241000320412 Ogataea angusta Species 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 238000005277 cation exchange chromatography Methods 0.000 description 4
- 239000003593 chromogenic compound Substances 0.000 description 4
- 238000010219 correlation analysis Methods 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000002572 peristaltic effect Effects 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 238000011218 seed culture Methods 0.000 description 4
- 101150023946 MOX gene Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- VQLYBLABXAHUDN-UHFFFAOYSA-N bis(4-fluorophenyl)-methyl-(1,2,4-triazol-1-ylmethyl)silane;methyl n-(1h-benzimidazol-2-yl)carbamate Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1.C=1C=C(F)C=CC=1[Si](C=1C=CC(F)=CC=1)(C)CN1C=NC=N1 VQLYBLABXAHUDN-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000012160 loading buffer Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101100008044 Caenorhabditis elegans cut-1 gene Proteins 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000000222 eosinocyte Anatomy 0.000 description 2
- 239000012527 feed solution Substances 0.000 description 2
- 239000006052 feed supplement Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000003677 hemocyte Anatomy 0.000 description 2
- 229940000351 hemocyte Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 230000005622 photoelectricity Effects 0.000 description 2
- IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000237902 Hirudo medicinalis Species 0.000 description 1
- 102100031004 Histidine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- 101000843187 Homo sapiens Histidine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 108010018472 chromozym TH Proteins 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002086 displacement chromatography Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001723 fibrinogenic effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 1
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
储存时间 | 储存条件 | 直线方程 | 回归系数 | 抗凝活性(ATU/管) |
0天 | 4℃ | Y=-162.64X+0.5003 | 0.9908 | 3787 |
0天 | 室温 | Y=-171.97X+0.4809 | 0.9972 | 4166 |
45天 | 4℃ | Y=-227.22+0.6669 | 0.9789 | 3963 |
45天 | 室温 | Y=-236.52X+0.6437 | 0.9970 | 4281 |
90天 | 4℃ | Y=-218.95X+0.1350 | 0.9976 | 4724 |
90天 | 室温 | Y=-222.74X+0.1359 | 0.9948 | 4774 |
检测项目 | 检测样本数 | r(Spearman) | ICR |
白细胞总数(WBC) | 50 | 0.983** | 0.994** |
中性粒细胞数(NE) | 50 | 0.954** | 0.986** |
淋巴细胞数(LY) | 50 | 0.853** | 0.790** |
单核细胞数(MO) | 50 | 0.918** | 0.927** |
嗜酸粒细胞数(EO) | 50 | 0.805** | 0.766* |
噬碱粒细胞数(BA) | 50 | 0.846** | 0.826** |
中性粒细胞% | 50 | 0.985** | 0.987** |
淋巴细胞% | 50 | 0.992** | 0.994** |
单核细胞% | 50 | 0.713** | 0.798** |
嗜酸粒细胞% | 50 | 0.701** | 0.755** |
嗜碱粒细胞% | 50 | 0.714** | 0.721** |
红细胞计数(RBC) | 50 | 0.978** | 0.976** |
血红蛋白(HGB) | 50 | 0.970** | 0.989** |
红细胞比积(HCT) | 50 | 0.902** | 0.607** |
红细胞平均容积(MCV) | 50 | 0.941** | 0.946** |
红细胞平均血红蛋白(MCH) | 50 | 0.824** | 0.925** |
红细胞平均血红蛋白浓度(MCHC) | 50 | 0.839** | 0.918** |
红细胞分布宽度(RDW) | 50 | 0.949** | 0.963** |
血小板计数(PLT) | 50 | 0.984** | 0.973** |
平均血小板容积(MPV) | 50 | 0.943** | 0.958** |
血小板分布宽度(PDW) | 50 | 0.878** | 0.933** |
检测项目 | 检测样本数 | r(Spearman) | ICR |
谷氨酰转移酶(GGT) | 50 | 0.942** | 0.921** |
谷丙转氨酶(ALT) | 50 | 0.969** | 0.998** |
碱性磷酸酶(ALP) | 50 | 0.929** | 0.997** |
谷草转氨酶(AST) | 50 | 0.960** | 0.997** |
总蛋白(TP) | 50 | 0.829** | 0.872** |
白蛋白(ALB) | 50 | 0.975** | 0.969** |
球蛋白(GLO) | 50 | 0.934** | 0.947** |
总胆红素(TB) | 50 | 0.870** | 0.953** |
尿素(Urea) | 50 | 0.985** | 0.992** |
肌酐(Cr) | 50 | 0.979** | 0.988** |
尿酸(UA) | 50 | 0.965** | 0.980** |
葡萄糖(GLU) | 50 | 0.952** | 0.992** |
总胆固醇(TC) | 50 | 0.986** | 0.988** |
甘油三酯(TG) | 50 | 0.930** | 0.964** |
高密度脂蛋白胆固醇(HDL-C) | 50 | 0.922** | 0.932** |
低密度脂蛋白胆固醇(LDL-C) | 50 | 0.972** | 0.980** |
肌酸激酶(CK) | 50 | 0.962** | 0.996** |
乳酸脱氢酶(LDH) | 50 | 0.933** | 0.993** |
羟丁酸脱氢酶(HBDH) | 50 | 0.904** | 0.994** |
钠离子(Na) | 50 | 0.922** | 0.952** |
钾离子(K) | 50 | 0.941** | 0.938** |
氯离子(Cl) | 50 | 0.857** | 0.853** |
钙(Ca) | 50 | 0.938** | 0.929** |
磷(P) | 50 | 0.898** | 0.931** |
项目 | 检测样本数 | r(Spearman) | ICR | |
全血黏度,高切 | 1/200S | 50 | 0.902** | 0.9654** |
全血年度,中切 | 1/30S | 50 | 0.933** | 0.9986** |
全血年度,低切 | 1/5S | 50 | 0.890** | 0.8799** |
全血年度,低切 | 1/S | 50 | 0.939** | 0.9089** |
血浆黏度 | 50 | 0.975** | 0.9719** | |
血沉 | ESR | 50 | 0.982** | 0.9866** |
红细胞比积 | Hct | 50 | 0.843** | 0.7198** |
全血高切还原黏度 | RH | 50 | 0.690** | 0.7269** |
全血低切还原黏度 | RL | 50 | 0.940** | 0.9250** |
全血高切相对指数 | Hl | 50 | 0.906** | 0.9561** |
全血低切相对指数 | Cl | 50 | 0.845** | 0.9096** |
血沉方程K值 | EK | 50 | 0.976** | 0.9854** |
红细胞聚集指数 | RHl | 50 | 0.895** | 0.8936** |
红细胞刚性指数 | RLl | 50 | 0.963** | 0.9510** |
红细胞变形指数 | TK | 50 | 0.860** | 0.8513** |
纤维蛋白原 | Fig | 50 | 0.967** | 0.9811** |
项目 | 检测样本数 | 检测结果 | BD采血管 | 通用真空采血管 |
乙型肝炎表面抗原 | 5050 | 阴性(-)阳性(+) | 3812 | 3812 |
丙型肝炎抗体 | 5050 | 阴性(-)阳性(+) | 464 | 464 |
项目与结果 | 样本数 | BD采血管 | 通用真空采血管 |
阴性 | 20 | 20 | 20 |
乙型肝炎病毒DNA2-2.5×10<sup>6</sup>拷贝 | 2 | 2 | 2 |
乙型肝炎病毒DNA3-4×105拷贝 | 5 | 5 | 5 |
乙型肝炎病毒DNA2-5×104拷贝 | 3 | 3 | 3 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101031552A CN101248998B (zh) | 2008-03-31 | 2008-03-31 | 一种真空采血管 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101031552A CN101248998B (zh) | 2008-03-31 | 2008-03-31 | 一种真空采血管 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101248998A CN101248998A (zh) | 2008-08-27 |
CN101248998B true CN101248998B (zh) | 2010-12-08 |
Family
ID=39952724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101031552A Expired - Fee Related CN101248998B (zh) | 2008-03-31 | 2008-03-31 | 一种真空采血管 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101248998B (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9113836B2 (en) | 2009-03-02 | 2015-08-25 | Seventh Sense Biosystems, Inc. | Devices and techniques associated with diagnostics, therapies, and other applications, including skin-associated applications |
WO2012018486A2 (en) | 2010-07-26 | 2012-02-09 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or receiving of fluids |
CN101695446B (zh) * | 2009-10-30 | 2011-01-12 | 天津市百利康泰生物技术有限公司 | 一次性软接带收集容器及放血口的抗凝真空采血针 |
CN101695447B (zh) * | 2009-10-30 | 2011-08-31 | 天津市百利康泰生物技术有限公司 | 一次性硬接带收集容器及放血口的抗凝真空采血针 |
CN101785676B (zh) * | 2010-02-08 | 2011-02-09 | 天津市百利康泰生物技术有限公司 | 一次性软连接水蛭素抗凝横式真空采血套件 |
CN101803926B (zh) * | 2010-02-08 | 2011-08-31 | 天津市百利康泰生物技术有限公司 | 一次性软连接并联多管水蛭素抗凝采血连接器 |
WO2012021801A2 (en) | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
WO2012149155A1 (en) | 2011-04-29 | 2012-11-01 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
US20130158468A1 (en) | 2011-12-19 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
KR20140034200A (ko) * | 2011-04-29 | 2014-03-19 | 세븐쓰 센스 바이오시스템즈, 인크. | 혈액 스폿들 또는 다른 신체 유체들을 수집 및/또는 조작하기 위한 시스템들 및 방법들 |
EP2701600B1 (en) | 2011-04-29 | 2016-06-08 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving fluids |
CN104510481A (zh) * | 2013-09-26 | 2015-04-15 | 温州市高德医疗器械有限公司 | 高血压三项酶抑制剂真空采血管及其制作方法 |
WO2021124847A1 (ja) * | 2019-12-18 | 2021-06-24 | 積水メディカル株式会社 | 血液採取容器 |
CN113080961B (zh) * | 2021-03-16 | 2023-02-10 | 宁波博睿瀚达生物科技有限公司 | 一种无内毒素的水蛭素抗凝血真空采血管及其制备方法 |
-
2008
- 2008-03-31 CN CN2008101031552A patent/CN101248998B/zh not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
Hans D. Menssen等.The Use of Hirudin as Universal Anticoagulant inHaematology, Clinical Chemistry and Blood Grouping.Clinical Chemistry and Blood Grouping39 12.2001,39(12),1267-1277. * |
HansD.Menssen等.TheUseofHirudinasUniversalAnticoagulantinHaematology Clinical Chemistry and Blood Grouping.Clinical Chemistry and Blood Grouping39 12.2001 |
陈萍等.水蛭素及其重组技术的研究进展.中药新药与临床药理17 5.2006,17(5),390-393. |
陈萍等.水蛭素及其重组技术的研究进展.中药新药与临床药理17 5.2006,17(5),390-393. * |
Also Published As
Publication number | Publication date |
---|---|
CN101248998A (zh) | 2008-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101248998B (zh) | 一种真空采血管 | |
CN100556546C (zh) | 在血液收集过程中去除成分的装置及其使用 | |
Sas et al. | Investigations on antithrombin III in normal plasma and serum | |
Kay et al. | The identification of fibrinopeptide B as a chemotactic agent derived from human fibrinogen | |
CHERNOFF et al. | The amino acid composition of hemoglobin. II. Analytical technics | |
CN101250530B (zh) | 一种重组水蛭素编码基因与应用 | |
CN201234980Y (zh) | 一种真空采血管 | |
Dorer et al. | Angiotensin converting enzyme: method of assay and partial purification | |
CN101857635A (zh) | 一种牛血浆中三种蛋白质的连续分离方法 | |
Lyttleton | The antithrombin activity of human plasma | |
CN105669858B (zh) | 一种从血浆Cohn法组分IV沉淀中提取抗凝血酶III和多种功能蛋白的方法 | |
Tucker et al. | The M‐L blood group system and its influence on red cell potassium levels in sheep | |
Bergqvist et al. | Effect of use of gel-barrier sampling tubes on determination of some antiepileptic drugs in serum. | |
GB1418849A (en) | Production of antisera | |
WO2012035508A4 (en) | Method for separating target molecules or particles from fibrinogen-containing samples including blood components | |
CN1168986C (zh) | 黄曲霉毒素快速检测装置及其制造方法 | |
CN102654505A (zh) | 一种检测il-2-hsa的时间分辨荧光免疫分析试剂盒及其检测方法 | |
CN1250718C (zh) | 蝰蛇蛇毒血凝酶的层析纯化方法 | |
CN109354621A (zh) | 一种天然凝血酶调节蛋白的纯化方法 | |
CN113398251B (zh) | 一种重组人绒毛膜促性腺激素冻干粉针剂及其制备方法 | |
Owen et al. | Antihemophilic factor. A new method for purification | |
Norén | Specific Assay of Prothrombin: A Method Using a Freeze-dried Reagent of Intrinsic Coagulation Factors | |
CN103293253A (zh) | 生物技术药物高效纯化分析系统及其药物分离检测方法 | |
CN104311656B (zh) | cFGF‑21蛋白及其在治疗类风湿关节炎中的应用 | |
CN1195228C (zh) | 一种肝素靶酶的筛选方法及其专用多功能微流控芯片 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: WANG HEMU Effective date: 20131217 Owner name: WANG HEMU Free format text: FORMER OWNER: TIANJIN CHAORAN BIOLOGICAL TECHNOLOGY CO., LTD. Effective date: 20131217 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 300192 NANKAI, TIANJIN TO: 300071 NANKAI, TIANJIN |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131217 Address after: 300071, No. 4, gate 68, 308 Southwest Village, Nankai University, Tianjin, Nankai District Patentee after: Wang Hemu Address before: 300192 173, research center, 12 West research road, Tianjin, Nankai District Patentee before: Tianjin Chaoran Biological Technollogy Co., Ltd. Patentee before: Wang Hemu |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101208 Termination date: 20150331 |
|
EXPY | Termination of patent right or utility model |